CN104367593A - New application of periplaneta americana - Google Patents
New application of periplaneta americana Download PDFInfo
- Publication number
- CN104367593A CN104367593A CN201410344715.9A CN201410344715A CN104367593A CN 104367593 A CN104367593 A CN 104367593A CN 201410344715 A CN201410344715 A CN 201410344715A CN 104367593 A CN104367593 A CN 104367593A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- periplaneta americana
- infertility
- purposes according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of periplaneta americana or extractive thereof to prepare medicines treating infertility. Research shows that periplaneta americana or the extractive thereof is capable of effectively improving the reproductive endocrine functions and promoting follicular development and ovulation, has good treatment effect on infertility, and is definite in curative effect especially aiming at androgen-led infertility.
Description
Technical field
The present invention relates to the novelty teabag of periplaneta americana.
Background technology
Infertility refer to normal rule sexual life, do not take contraceptives and 2 years not pregnant persons.Along with the development of society, the quickening of rhythm of life and the continuous increase of operating pressure, the factors such as late marriage and childbirth, artificial abortion, sexually transmitted disease (STD) increase, infertility sickness rate is obvious ascendant trend, accounts for 8% ~ 17% of Women in menopause.Infertility is commonly encountered diseases, difficult treatment, also can change into marital problem and domestic problem under certain condition.
【1】
According to the standard that CAIM (Chinese Association Of Integrative Medicine) is worked out for 1991, after all women marries, or after last gestation, the normal and bridegroom's or husband's side reproductive function of couples sex life normally, is lived together more than 1 year and is not taked contraceptives and can not the person of becoming pregnant, be called infertility.The research data display of World Health Organization (WHO), the whole world about has the Mr. and Mrs of 12% ~ 16% sterile, and the ovulation failure in the cause of disease caused by ovarian hypofunction, endocrine disturbance accounts for 31% ~ 40%
[2], the incidence rate of China women of child-bearing age Ovulation barrier sterile is about 15% ~ 38.6%
[3].Infertility not only has influence on each marriage, family, and is global reproduction Jiankang problem equally.The mankind are just in the healthy reproduction of growing interest self, the fertility right of often couple of healthy women of child-bearing age and obtain healthy requirement and make the research of infertility become urgent and day by day to cause people a to pay close attention to problem gradually, effectively preventing and treating primary disease has become the important topic that today, medical domain was studied.In recent years, along with the development of medical science and auxiliary procreation technology, the treatment of infertility has greatly changed.
Before more than 2,000 years, " Plain Questions ancient times innocence opinion " oneself have record about reproductive physiology, successive dynasties gynecological doctor nationality all has the description of " loss of fecundity ", " entirely not producing ", " breaks ", " without offspring ", and wards off the treatment of a special section to infertility and discuss.And to modern age, many scholars, in the clinical and basic research of the traditional Chinese medical science and therapy of combining Chinese and Western medicine infertility, conduct in-depth research, and have achieved challenging progress.The kidney being the origin of congenital constitution, the root of vigour, main reproduction, secretes menses.Appoint main vessels of the uterus, lie in kidney.Therefore the relation of infertility and kidney is very close.
Doctor trained in Western medicine
[4]think that normal ovulation needs hypothalamic-pituitary-ovarian gonad index normal, any link functional disorder, or organic disease, all can cause ovarian dysfunction to cause anovulation.In treatment, general for the purpose of the growth bringing out single follicle or minority follicle, employing clomifene citrate (cc), urine trophic hormone (HMG), Gonadex (HcG), restructuring FsH, gonadotropin releasing hormone and analog thereof carry out Ovarian hyperstimulation; Implement treatment-resistant for thyroid function, dysadrenalism, and auxiliary procreation technology (ART).But Drug therapy exists that induced ovulation rate is high, pregnancy rate is low, untoward reaction is serious, usage and dosage are difficult to the drawbacks such as grasp; ART is then high because of its price, and success rate is low, relates to the problems such as social morality and can not be accepted by patient.So the hypotoxicity of Chinese medicine, high efficiency, the Advantages found for the treatment of both the principal and secondary aspects of a disease out.
Periplaneta americana is Insecta Pterigota Lian order Blattidae Periplaneta insect, and be commonly called as " Blatta seu periplaneta ", its beginning of being used as medicine is loaded in Shennong's Herbal, and it is classified as middle product, meaning " taste: salty, cold; Control: the hard cold and heat of Blood stasis, removing mass are poly-, throat closes
[5]".Yet there are no modern medicine and pharmacology research periplaneta americana being used for the treatment of infertility.
Summary of the invention
The object of the present invention is to provide the novelty teabag of a kind of periplaneta americana or its extract.
The invention provides periplaneta americana or the purposes of its extract in the medicine of preparation treatment infertility.
Further, described medicine is the medicine for the treatment of blood stasis due to renal deficiency infertility.
Further, described medicine is the medicine that treatment androgen causes infertility.
Further, described medicine is the medicine improving reproductive endocrine function.
Further, described medicine promotes follicular development or/and the medicine of ovulation.
American-cockroach-extract of the present invention, meets the limit standard to " Kangfuxin Liquid " in WS3-B-3674-2000 (Z), and every 1ml must not lower than 0.72mg containing total amino acids, as commercially available Kangfuxin Liquid.
Or, meet in WS3-B-3674-2000 (Z) and the limit standard of " extract of the dry polypide of periplaneta americana Perip leneta ameri Cana " also can, calculate according to dry product, must not be less than 7.0% containing total amino acids, the rehabilitation as commercially available is new.Kangfuxin Liquid is the solution be prepared from by Kangfuxin Liquid.In addition, American-cockroach-extract preparation method common at present also can be used to be prepared, such as:
Get periplaneta americana, pulverize, 70 ~ 90%v/v ethanol extraction, merge extractive liquid, after reclaiming ethanol, add water mixing, heated and stirred, leaves standstill, and cooling, makes oils and fats fully float, take off clear liquid, concentrates or namely obtain American-cockroach-extract after drying.
In the specific embodiment of the invention, the medicine used for through gastrointestinal administration preparation, such as, uses granule, tablet, capsule, pill, powder, oral liquid or other gastrointestinal administration preparations.
Although select in the specific embodiment of the invention through gastrointestinal absorption preparation to embody the therapeutic effect of pharmaceutical composition, but this can not be used for the form of medication limiting pharmaceutical composition of the present invention.In conjunction with modern separating and purifying technology or/and preparation means, those skilled in the art also can by after periplaneta americana or its extract purification, be prepared into other form of medication such as transdermal absorption formulation, external-use lotion, et al. Ke preparation, injection, thus strengthen target-oriented drug, improve drug effect or avoid unnecessary toxicity.
Medicine of the present invention, be with periplaneta americana (as periplaneta americana medicated powder) or American-cockroach-extract for active component, add the preparation that pharmaceutically conventional adjuvant or complementary composition are prepared from.
Pharmaceutically acceptable adjuvant of the present invention, refer to the material be included in addition to the active ingredient (s in dosage form, include but are not limited to filler (diluent), lubricant (fluidizer or antitack agent), dispersant, wetting agent, binding agent, regulator, solubilizing agent, antioxidant, antibacterial, emulsifying agent, disintegrating agent etc.Binding agent comprises syrup, arabic gum, gelatin, sorbitol, tragacanth, cellulose and its derivates (as microcrystalline Cellulose, sodium carboxymethyl cellulose, ethyl cellulose or hydroxypropyl methylcellulose etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivant thereof, cellulose and its derivates, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate etc.), sorbitol or glycine etc.; Lubricant comprises micropowder silica gel, magnesium stearate, Pulvis Talci, aluminium hydroxide, boric acid, hydrogenated vegetable oil, Polyethylene Glycol etc.; Disintegrating agent comprises starch and derivant (as carboxymethyl starch sodium, Explotab, pregelatinized Starch, modified starch, hydroxypropyl starch, corn starch etc.), polyvinylpyrrolidone or microcrystalline Cellulose etc.; Wetting agent comprises sodium lauryl sulphate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium sulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Antibacterial comprises 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol etc.; Regulator comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer agent (comprising phosphoric acid dioxy sodium and sodium hydrogen phosphate) etc.; Emulsifier package containing Tween-80, do not have that sour Pyrusussuriensis is smooth, pluronic gram F-68, lecithin, fabaceous lecithin etc.; Solubilizing agent comprises tween 80, bile, glycerol etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change above-mentioned health product or the leading position of pharmaceutical composition in treatment of diseases, and only play auxiliary effect, these auxiliary effects are only the utilizations to this composition known activity, are the usual adjuvant treatment modality of field of medicaments.
The present invention's research shows, periplaneta americana or its extract effectively can improve reproductive endocrine function, promotes follicular development and ovulation, has good therapeutical effect, cause infertility clear curative effect especially for androgen to infertility.
Obviously, according to foregoing of the present invention, according to ordinary technical knowledge and the means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of other various ways, replacement or change can also be made.
Below by way of the form of specific embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
The Kangfuxin Liquid used in the present invention, meets WS3-B-3674-2000 (Z) regulation.
Embodiment 1 drug activity is tested
1 materials and methods
1.1 experiment material
1.1.1 laboratory animal
Select the female sd inbred rats children Mus 80 of breeding phase same time birth of selecting a time, weaned by female Mus suckling to 22 age in days after birth.Raised by special messenger.Be divided into normal group and experimental group at random, normal group is 10, experimental group 70.
1.1.2 experimental drug
Testosterone propionate injection: 25mg/ml, Tianjin KingYork Amino Acid Co., Ltd., lot number: 0501081, purchased from Affiliated Hospital of Chengdu University of Traditional Chinese Medicine first.
1.1.3 experiment equipment
1m1 syringe, disinfecting cotton swab, common slide, medical microscope.
1.1.4 staining reagent
95% ethanol, 75% ethanol, HarriS haematoxylin, orange G, phosphotungstic acid, viride nitens sF, Yihong y, upright stone tablet scholar wheat palm fibre, phosphotungstic acid, lithium carbonate.
1.2 experiment condition
Room temperature about 20 DEG C, ventilates clean, humidity 55 scholar 5%, and feedstuff, moisture is sufficient, sub-cage rearing under quiet environment.
1.3 modeling method
1.3.1 Animal Model
With reference to Yu Jin etc.
[6]experimental technique sets up anovulatory rats model (i.e. androgen sterihzed rat model, ASR).Get the 9th age in days female sd inbred rats 60 (experimental group), in neck dorsal sc injection testosterone propionate 1.25mg/ only (0.05mL/ only).To the 70th age in days vaginal opening.Equally, get the 9th age in days female sd inbred rats 10 (normal group), in neck dorsal sc injection equivalent distilled water, to the 70th age in days vaginal opening.Experimental group and normal group are all in the 22nd age in days wean, and utilize natural lighting, room temperature maintains about 20 DEG C, and similarity condition is raised, and is fed by special messenger.
1.3.2 animal model observational technique
Vaginal opening is observed time experimental group rat the 70th age in days (rat body weight is about about 150g).Perusal rat vagina secretions consecutive row vaginal smear 10 days (i.e. 2 sexual cycles), 95% alcohol fixation, pap staining, dry, mounting, observes under juxtaposition ordinary optical microscope, understands rat vagina epithelium and changes with or without sexual cycle, same vaginal smear 2 sexual cycles continuously of normal group, observe its vaginal epithelial cell and change with or without sexual cycle.
1.3.3 Rats During The Estrous Cycle change criterion
Transvaginal exfoliative cyte smear is observed rat vagina epithelial cell and is presented and have core epithelial cell and a small amount of superficial cell in a large number, be covered with superficial cell and have the cyclically-varying of core epithelial cell, superficial cell and leukocyte, a large amount of leukocyte and a small amount of mucus on a small quantity, and prompting rat has regular sexual cycle change
[7].
1.3.4 animal model modeling successfully judges
Experiment transvaginal exfoliative cyte smear is observed vaginal epithelial cell and is continuously seedless keratinocyte, points out its asexual mechanical periodicity, modeling success.If rat vagina epithelial cell observed by smear present the change of above sexual cycle, then eliminate experimental group.
2 results
2.1 observation of symptoms
Experimental group Hair of Rats is withered, matt, come off, ear color is dark red, pawl afterbody is purple dark.Its vaginal secretions of perusal is dry and astringent.Normal rats is grown normal, performance without exception.
2.2 smears are observed
Observe through smear, experimental group 70 participates in modeling rat, wherein 60 asexual mechanical periodicity, can find out that its cell is continuously seedless keratinocyte from smear, retain for subsequent use, participate in remaininging of modeling in experimental group and 10 only have typical or atypical sexual cycle to change, reject.60 successful rats of modeling are retained for subsequent use.Normal group 10 injection distilled water, observe rat vagina exfoliative cyte from smear and all have regular sexual cycle change, retain for subsequent use.
1. materials and methods
1.1 animal
The successful experimental group of modeling 60 and normal group 10 SD rats.
1.2 medicines and reagent
1.2.1 medicine
1) periplaneta americana medical material is beaten powder and is sieved;
2) Kangfuxin Liquid M1204182 Hunan Central South Kelun Medicine Co., Ltd..
3) Chloramiphene (cc): 50mg/ grain, Heng Shan, Shanghai pharmaceutcal corporation, Ltd, lot number: 120801,
1.2.2 reagent
IGFBP-lmRNA in situ hybridization test kit Shi De biological engineering company limited.
IGFBP mono-3mRNA in situ hybridization test kit Shi De biological engineering company limited.
4% paraformaldehyde fixative etc.
1.3 instrument
Operating theater instruments 5 is overlapped, liquid-transfering gun 3, centrifuge, and EP pipe is some, electronic balance, common slide, medical microscope
1.4 method
1.4.1 experiment condition
Room temperature about 20 DEG C, humidity 65 ± 5%, ventilates, clean, feedstuff, feedwater abundance, quiet.Animal sub-cage rearing.Laboratory environment meets the requirement of regular grade Animal Lab..
I.4.2 group technology
Dosage group, periplaneta americana medical material high dose group in model group, positive drug group, Kangfuxin Liquid group, periplaneta americana medical material low dose group, periplaneta americana medical material is divided into often to organize each 10 60 experimental group rats by random digits table, and normal group 10.
L.4.3 medication
After animal pattern has divided into groups, from 80 ages in days, following administration respectively.Periplaneta americana adult 10g medical material every day calculates, periplaneta americana beats powder and sieves, dissolving low dosage assembly with carboxymethylcellulose sodium solution is 0.1g/ml, middle dosage is 0.2g/ml, high dose is 0.4g/ml, Kangfuxin Liquid presses 1ml/100g rat dosage gavage, Chloramiphene (cc) (4.5mg/ (kgd)) gavage.Testing index after continuous gavage surrounding.
1.5 collections of specimens and Indexs measure
1.5.1 vaginal exfoliated inspection
Administration the 4th week timing in morning every day disinfecting cotton swab is got rat vagina exfoliative cyte and is made smear, continuous 1 sexual cycle.95% alcohol fixation, pap staining, dries, mounting, observes under putting ordinary optical microscope.
1.5.2 rat ovary is weighed
Each group of continuous gavage all sacrificed by decapitation after 28 days, cuts abdominal cavity open, takes out bilateral ovaries, remove peripheral adipose tissue, ovary is put scales/electronic balance weighing rapidly.Ovarian morphology and ovary IGFBP-lmRNA, IGFBP-3mRNA Indexs measure.By the side ovary taken out, put into 4% paraformaldehyde after peeling off fatty tissue around and fix, censorship.By the opposite side ovary taken out, after peeling off fatty tissue around with 4% paraformaldehyde fix, censorship.
1.6 statistical method
The x2 inspection of enumeration data week, ranked data rank test, measurement data variance analysis, compare between group with LSD inspection, the machine process as calculated of SPSS12.0 statistical software is all used in all computings.
2 results
2.1 periplaneta americanaes are on the impact of rat ovary.
2.1.1 rat vagina exfoliative cyte smear is observed, and observes through ordinary optical microscope, and the former vaginal epithelial cell in continuing keratinization state of vaginal exfoliated cell smear starts to occur that the oestrous cycle changes.Each group there is the number of cases of oestrous cycle and the comparative result of ovulation rate, in Table l
On the impact of ASR oestrous cycle and ovulation rate after table 1 administration
Note: compare with model group: ★ P<0.05
Table 1 result illustrates: model group and normal group comparing difference have statistical significance (P<0.05), and prompting ASR has the pathological change of ovulation failure; Other administration groups have statistical significance (P<0.05) with model group is more variant, and prompting periplaneta americana, Kangfuxin Liquid and cc can induce the oestrous cycle of AsR, improve ovulation rate; Administration group and normal group comparing difference not statistically significant (P>0.05), point out by periplaneta americana medicine, Kangfuxin Liquid and CC treatment, and ASR oestrous cycle and ovulation rate can be made to recover close to normal; Between medical material group and positive drug group group, comparing difference is pointed out without statistically meaning (P>0.05): periplaneta americana medical material can induce the oestrous cycle of ASR, improve ovulation rate, similar to CC effect.To sum up illustrate, periplaneta americana may have the effect regulating rat reproductive endocrine function, facilitates follicular development and ovulation.
2.1.2 the gross examination of skeletal muscle of rat ovary
Model group ovary is pale, and follicle is seen on surface, but Follicle number is few, and follicle is less, without corpus luteum.Normal group and Chinese drug-treated group and Western medicine group rat ovary color and luster scarlet, Follicle number is obviously more than model group, and follicle obviously increases, and more corpus luteum is seen on surface.
2.1.3 rat ovary weight
with folliculus ovarii number
relatively
After table 2 administration, rat ovary weight and folliculus ovarii number compare
Note: compare with model group: ※ P<0.05; With normal group: ▲ P<0.05; Compare with positive group: △ P<0.05.
Table 2 result illustrates: model group and normal group comparing difference in ovary weight and Follicles number has statistical significance (P<0.05), and prompting ASR has ovary weight and alleviates, the pathological change that Follicles number reduces; Administration group and model group comparing difference in ovary weight and Follicles number has statistical significance (P<0.05), and prompting periplaneta americana, Kangfuxin Liquid, cc can increase rat ovary weight and Follicles number; Each administration group and normal group be comparing difference not statistically significant (P>0.05) in ovary weight, and prompting periplaneta americana medical material, Kangfuxin Liquid, cc increase rat ovary weight, close to normal; Periplaneta americana group, Kangfuxin Liquid group and normal group be comparing difference not statistically significant (P>0.05) on Follicles number, prompting: periplaneta americana powder, Kangfuxin Liquid can increase rat ovary Follicles number, makes it close to normal; Periplaneta americana, Kangfuxin Liquid and positive drug group comparing difference on Follicles number has statistical significance (P<0.05), prompting: the effect in increase rat ovary Follicles number of periplaneta americana, Kangfuxin Liquid is better than positive drug cc.To sum up illustrate, periplaneta americana recovers the ovarian morphology of rat, facilitates follicular development and ovulation, and effect is better than cc.
2.2 periplaneta americanaes are on the impact of rat ovary IGFBP-ImRNA
Table 3: each expression intensity of group rat ovary IGFBP-lmRNA and the comparison (x ± S) of positive cell number
| Group | Number of animals (only) | Average gray | Positive cell number |
| Normal group | 10 | 74.12±12.38 △ | 294.18±33.07 △ |
| Model group | 10 | 150.95±25.79 | 170.21±51.47 |
| Positive group | 10 | 120.44±27.66 ▲ | 225.16±34.12 ▲ |
| Kangfuxin Liquid group | 10 | 99.48±19.47 ▲※ | 238.89±33.09 ▲※ |
| Medical material low dosage | 10 | 98.17±15.81 ▲※ | 240.13±34.79 ▲※ |
| Dosage in medical material | 10 | 90.21±16.83 ▲※ | 249.10±34.18 ▲※ |
| Medical material high dose | 10 | 85.47±14.74 ▲※ | 258.75±34.92 ▲※ |
Note: gray value is less, expresses stronger.Compare with model group: ▲ P<0.05; Compare with normal group: △ P<0.05; Compare with positive group: ※ P<0.05.
The explanation of table 3 result, the expression intensity of model group rats ovary IGFBP-lmRNA and positive cell number and normal group comparing difference have statistical significance (P<0.05), point out rat after giving exogenous androgen, make ovary IGFBP-lmRNA express reduce from pathological change; Administration group and model group comparing difference on expression intensity and positive cell number has statistical significance (P<0.05), point out after periplaneta americana, Kangfuxin Liquid and cc treatment from response to treatment, rat ovary IGFBP-lmRNA can be made to express and raise; Periplaneta americana, between Kangfuxin Liquid group and positive group of group, on expression intensity, comparing difference has statistical significance (P<0.05), points out rat ovary IGFBP-lmRNA can be made to express raise and effect is better than CC through periplaneta americana powder, Kangfuxin Liquid from medicine.To sum up illustrate, periplaneta americana, Kangfuxin Liquid can strengthen the expression of ASR rat ovary IGFBP-lmRNA, illustrate that IGFBP-1 may play a role in the growth of dominant follicle.
2.3 periplaneta americanaes are on the impact of rat ovary IGFBP mono-3mRNA
Table 4: each expression intensity of group rat ovary IGFBP mono-3mRNA and the comparison of positive cell number
Note: gray value is larger, expresses more weak.Compare with model group: ▲ P<0.05; Compare with normal group: ※ P<0.05.
The explanation of table 4 result, model group rats ovary IGFBP-3mRNA has statistical significance (P<0.05) with normal group comparing difference on expression intensity and positive cell number, points out rat that ovary IGFBP-3mRNA can be made after giving exogenous androgen to express raise from pathological change; Administration group and model group comparing difference on expression intensity and positive cell number has statistical significance (P<0.05), points out after Drug therapy from response to treatment, rat ovary IGFBP-3mRNA can be made to express and reduce; Administration group and normal group comparing difference on expression intensity and positive cell number has statistical significance (P<0.05), points out after Drug therapy from treatment level, and rat ovary IGFBP-lmRNA expresses and reduces not as good as normal group; Between periplaneta americana group and positive drug group group, comparing difference not statistically significant (P>0.05), points out through periplaneta americana from medicine, makes rat ovary IGFBP-3mRNA express reducing effect similar after cc treatment.To sum up illustrate: periplaneta americana can reduce ASR rat ovary IGFBP-3 level, makes it to reduce with the combination of IGFs, adds the concentration of free IGFs, enhances the biologic activity of tGFs, facilitate growth and the ovulation of follicle.
List of references:
[1] Chinese medicine progress [J] of Zhao Zhidan infertility. folks of china therapy, 2013,21 (3): 75-77
[2] Wei Mei beautiful Yu Jin kidney-nourishing tcm drug is to androgen sterihzed rat Morphological Changes of Adrenal Cortex [J]. Chinese combination of Chinese and Western medicine magazine, 1994,14 (12): 736-738.
[3] Chen Zhuchu, the raw chief editor of sky end. experimental zoology [M] (first edition). Hunan: Hunan Science Press, 2006; 77-81
[4] Bbarraclough CA.ProductiOil of anovl.latory Sterile rats by single injection of testosterone propionate [J] .Endicrino mono-109y196I:68:62-67.
[5] Sun Xingyan. Sheng Nong's herbal classic [M]. Beijing: Commercial Press .1955:90.
[6] Yu Jin. anovulatory infertility [J]. combination of Chinese and Western medicine magazine, 1987,7 (10): 617-618.
[7] Luo Lilan chief editor. IVF-ET (first edition) [M]. Beijing: People's Health Publisher .1998:202.
[8] LUO YUANKAI. LUO YUANKAI opinion doctor collection. Beijing: People's Health Publisher .1990.38
[9] Ye Jianhong. shallow view animal model with TCM syndrome makes [J]. Colleges Of Traditional Chinese Medicine Of Guangxi's journal, 2001,4 (2): 79.
[10] Chen little Ye etc. Chinese Medicine journal, 2 (1): 1987.
Claims (10)
1. periplaneta americana or its extract purposes in the medicine of preparation treatment infertility.
2. purposes according to claim 1, is characterized in that: described medicine is the medicine for the treatment of blood stasis due to renal deficiency infertility.
3. purposes according to claim 1, is characterized in that: described medicine is the medicine that treatment androgen causes infertility.
4. the purposes according to claims 1 to 3 any one, is characterized in that: described medicine is the medicine improving reproductive endocrine function.
5. the purposes according to claims 1 to 3 any one, is characterized in that: described medicine promotes follicular development or/and the medicine of ovulation.
6. the purposes according to Claims 1 to 5 any one, is characterized in that: described American-cockroach-extract, and every 1ml must not lower than 0.72mg containing total amino acids.
7. purposes according to claim 6, is characterized in that: described American-cockroach-extract is Kangfuxin Liquid.
8. the purposes according to claim 1 ~ 6 any one, is characterized in that: described American-cockroach-extract, calculates, must not be less than 7.0% containing total amino acids according to dry product.
9. purposes according to claim 8, is characterized in that: described American-cockroach-extract is that rehabilitation is new.
10. the purposes according to Claims 1 to 5 any one, is characterized in that: described medicine is the preparation of active fraction preparation by the medicated powder of periplaneta americana.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410344715.9A CN104367593A (en) | 2013-08-13 | 2014-07-18 | New application of periplaneta americana |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310351122 | 2013-08-13 | ||
| CN2013103511220 | 2013-08-13 | ||
| CN201410344715.9A CN104367593A (en) | 2013-08-13 | 2014-07-18 | New application of periplaneta americana |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104367593A true CN104367593A (en) | 2015-02-25 |
Family
ID=52546954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410344715.9A Pending CN104367593A (en) | 2013-08-13 | 2014-07-18 | New application of periplaneta americana |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367593A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107007652A (en) * | 2016-01-28 | 2017-08-04 | 成都中医药大学 | Purposes of the Kangfuxin Liquid Combined with Chinese Herbal in the medicine for preparing treatment infertility |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254212A (en) * | 2008-03-25 | 2008-09-03 | 浙江大学 | Use of valid target of periplaneta americana |
| CN103070889A (en) * | 2013-01-21 | 2013-05-01 | 四川好医生攀西药业有限责任公司 | Periplaneta americana extract cream and preparation method thereof |
| CN103083363A (en) * | 2013-01-25 | 2013-05-08 | 四川好医生攀西药业有限责任公司 | Preparation method and new application of periplaneta americana extract |
-
2014
- 2014-07-18 CN CN201410344715.9A patent/CN104367593A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254212A (en) * | 2008-03-25 | 2008-09-03 | 浙江大学 | Use of valid target of periplaneta americana |
| CN103070889A (en) * | 2013-01-21 | 2013-05-01 | 四川好医生攀西药业有限责任公司 | Periplaneta americana extract cream and preparation method thereof |
| CN103083363A (en) * | 2013-01-25 | 2013-05-08 | 四川好医生攀西药业有限责任公司 | Preparation method and new application of periplaneta americana extract |
Non-Patent Citations (2)
| Title |
|---|
| 矫浩然: "《图解《神农本草经》》", 30 April 2014, 天津科学技术出版社 * |
| 谭兴贵 等: "《中国食物药用大典>", 31 July 2013, 西安交通大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107007652A (en) * | 2016-01-28 | 2017-08-04 | 成都中医药大学 | Purposes of the Kangfuxin Liquid Combined with Chinese Herbal in the medicine for preparing treatment infertility |
| CN107007652B (en) * | 2016-01-28 | 2020-06-30 | 成都中医药大学 | Application of new rehabilitation liquid combined with traditional Chinese medicine in preparation of medicine for treating infertility |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258685B (en) | Compound traditional Chinese medicine for treating diminished ovarian reserve and application | |
| WO2015127874A1 (en) | Traditional chinese medicine composition for treating type ii diabetes, and preparation and uses thereof | |
| CN113041312A (en) | Traditional Chinese medicine composition for treating premature ovarian failure and preparation method and application thereof | |
| CN101375968A (en) | Chinese medicinal composition as well as preparation method and application thereof | |
| CN103948771A (en) | Medicinal composition for treating infertility as well as preparation method and application of medicinal composition | |
| CN104367593A (en) | New application of periplaneta americana | |
| CN114081926B (en) | Traditional Chinese medicine Li medicine composition for reducing ovarian reserve function and preparation method and application thereof | |
| CN105943758B (en) | A kind of Chinese medicine composition that treating infertility and its application | |
| CN104645297B (en) | A kind of temperature palace helps pregnant Chinese medicine composition and its formulation preparation method | |
| CN107412555A (en) | It is a kind of to be used to treat medicine of ovulation failure and preparation method thereof | |
| Fraser et al. | Are fixed‐dose oestrogen/progestogen combinations ideal for all HRT users? | |
| CN111281867B (en) | Medicine for treating polycystic ovarian syndrome and preparation method thereof | |
| CN103479783A (en) | Chinese medicine composite for curing climacteric melancholia and application thereof | |
| CN104189356B (en) | A kind of pharmaceutical composition for the treatment of or auxiliary treatment infertility and its production and use | |
| US20150031775A1 (en) | Composition and method for affecting male and female hormone levels | |
| CN107334786B (en) | Bifidobacteria viable bacteria capsule and its application in preparing prevention premature ovarian failure drug | |
| CN107582948B (en) | Pharmaceutical composition for treating female irregular menstruation and preparation method and application thereof | |
| CN110354193A (en) | A kind of Traditional Chinese medicine compound composition and its application with treatment anovulatory infertility | |
| CN103520487B (en) | A kind of purposes of pharmaceutical composition | |
| Kareem et al. | Study of Physiological Changes Induced By Therapeutic Dose of Contraceptive Pills (Yasmin) in the Liver and kidneys of albino mice | |
| CN102049009B (en) | Application of pharmaceutical composition containing zedoary turmeric oil and borneol | |
| CN112741888B (en) | Traditional Chinese medicine composition for treating embryo diapause diseases and application thereof | |
| CN111905022B (en) | Medicine for promoting ovulation and preparation method thereof | |
| CN102114240B (en) | Application of medicament containing hirudin and cellosolve | |
| CN116440206A (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and/or low ovarian reserve function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190107 Address after: 615000 Xichang Airport Road, Sichuan Province Applicant after: Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd. Address before: Room 206, Building 5, Gaopeng Avenue, Chengdu High-tech Zone, Sichuan 610041 Applicant before: Chengdu Baicao Heji Technology Co., Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |